

Frank J Beurskens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5824929/publications.pdf>

Version: 2024-02-01

26
papers

2,061
citations

394421

19
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

2247
citing authors

#	ARTICLE	IF	CITATIONS
1	Biophysical Characterization and Stability of Modified IgG1 Antibodies with Different Hexamerization Propensities. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 1587-1598.	3.3	5
2	C1q binding to surface-bound IgG is stabilized by C1r ₂ s ₂ proteases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	32
3	Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen Recognition. <i>ACS Nano</i> , 2020, 14, 2739-2750.	14.6	36
4	Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2126-2138.	4.1	32
5	DuoHexaBody-CD37 ^Å , a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. <i>Blood Cancer Journal</i> , 2020, 10, 30.	6.2	43
6	Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. <i>PLoS Biology</i> , 2019, 17, e3000323.	5.6	59
7	Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces. <i>Nano Letters</i> , 2019, 19, 4787-4796.	9.1	79
8	CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. <i>Haematologica</i> , 2019, 104, 1841-1852.	3.5	38
9	Immune Effector Functions of Human IgG2 Antibodies against EGFR. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 75-88.	4.1	22
10	Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells". <i>Journal of Immunology</i> , 2018, 200, 2517-2517.	0.8	0
11	Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. <i>Science</i> , 2018, 359, 794-797.	12.6	127
12	Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells. <i>Journal of Immunology</i> , 2017, 198, 1585-1594.	0.8	20
13	Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. <i>Clinical Immunology</i> , 2017, 181, 24-28.	3.2	11
14	Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. <i>Journal of Immunology</i> , 2016, 197, 1762-1775.	0.8	50
15	Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. <i>Journal of Immunology</i> , 2016, 197, 4829-4837.	0.8	30
16	Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen. <i>Molecular Cell</i> , 2016, 63, 135-145.	9.7	139
17	Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. <i>Molecular Immunology</i> , 2016, 70, 13-23.	2.2	26
18	A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. <i>PLoS Biology</i> , 2016, 14, e1002344.	5.6	154

#	ARTICLE	IF	CITATIONS
19	Complement in therapy and disease. <i>Molecular Immunology</i> , 2015, 67, 117-130.	2.2	124
20	A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells. <i>Journal of Immunology</i> , 2015, 195, 5077-5087.	0.8	13
21	Complement in Antibody-Based Tumor Therapy. <i>Critical Reviews in Immunology</i> , 2014, 34, 199-214.	0.5	38
22	Complement Is Activated by IgG Hexamers Assembled at the Cell Surface. <i>Science</i> , 2014, 343, 1260-1263.	12.6	602
23	Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients. <i>Journal of Immunology</i> , 2012, 188, 3532-3541.	0.8	109
24	Penetration of antibody-opsinized cells by the membrane attack complex of complement promotes Ca^{2+} influx and induces streamers. <i>European Journal of Immunology</i> , 2011, 41, 2436-2446.	2.9	31
25	Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX. <i>Journal of Immunology</i> , 2009, 183, 749-758.	0.8	230
26	Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. <i>Blood</i> , 2008, 112, 4354-4355.	1.4	6